Table 1.
Patient and treatment characteristics (cohort A).
| Characteristic | Value |
|---|---|
| Gender | |
| Male | 14 (73.7%) |
| Female | 5 (26.3%) |
| Median age, years (range) | 67 (41–79) |
| ECOG | |
| 0 | 10 (52.6%) |
| 1 | 9 (47.4%) |
| Primary tumor | |
| Lung (non-squamous) | 11 (57.8%) |
| Lung (squamous) | 3 (15.8%) |
| Renal | 3 (15.8%) |
| Bladder | 1 (5.3%) |
| Cervix (squamous) | 1 (5.3%) |
| PD-L1 status (TPS) | |
| <50% | 3 (15.8%) |
| ≥50% | 9 (47.4%) |
| Unknown | 7 (36.8%) |
| Driver mutations | |
| Yes | 1 (5.3%) |
| No | 18 (94.7%) |
| Number of systemic therapy lines before SABR | |
| None | 12 (63.2%) |
| One | 7 (36.8%) |
| Prior radiotherapy | |
| Yes | 8 (42.1%) |
| No | 11 (57.9%) |
| Metastatic stage | |
| Oligometastatic (1–5 lesions) | 9 (47.4%) |
| Polymetastatic (>5 lesions) | 10 (52.6%) |
| Current systemic therapy | |
| ICI only | 15 (78.9%) |
| ICI plus chemotherapy | 4 (21.1%) |
| Primary resistance to ICI | |
| Yes | 4 (21.1%) |
| No | 15 (78.9%) |
| Irradiated tumor sites | |
| Lung | 10 (40%) |
| Nodes | 6 (24%) |
| Bone | 3 (12%) |
| Liver | 2 (8%) |
| Other | 4 (16%) |
| Number of irradiated sites | |
| One | 13 (62%) |
| Two | 6 (28%) |
| SABR dose | |
| 35 Gy/5 fx | 24 (98%) |
| 24 Gy/3 fx | 1 (2%) |
| Partial SABR | |
| Yes | 3 (15.4%) |
| No | 16 (84.2%) |
Abbreviations: ECOG = Eastern Cooperative Oncology Group; SABR = stereotactic ablative radiotherapy; ICI = immune checkpoint inhibitor; fx = fractions; PD-L1 = programmed cell death ligand 1, TPS = tumor proportion score.